When was Generation Bio founded?

Generation Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Generation Bio located?

Generation Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Generation Bio?

Geoff McDonough of Generation Bio.

How many employees does Generation Bio have?

As of Jan 31, 2026, the latest employee count at Generation Bio is 59.

Is Generation Bio a funded company?

Generation Bio is a funded company, having raised a total of $236M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 04, 2018.

How much is Generation Bio worth?

The last known valuation of Generation Bio was $***** as of Dec 15, 2025.

When was the latest funding round of Generation Bio?

Generation Bio's latest funding was a $***** Series C round on Jan 10, 2020, with participation from 10 investors.

What is the annual revenue of Generation Bio?

Annual revenue of Generation Bio is between $10M and $50M as on Dec 31, 2024

Where does Generation Bio rank among its competitors?

Generation Bio ranks 30th amongst 817 active competitors, of which 270 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Generation Bio?

Generation Bio's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Generation Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Generation Bio is an acquired company based in Cambridge (United States), founded in 2016 by Mark Angelino, Robert M Kotin and Mark Angelino. It operates as a Developer of gene therapies for rare liver and eye diseases. Generation Bio has raised $236M in funding from Fidelity Investments and T. Rowe Price, with last known valuation of $*****. The company has 817 active competitors, including 270 funded and 223 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of gene therapies for rare liver and eye diseases. The company provides non-viral gene therapies for phenylketonuria, hemophilia A, Wilson disease, Leber congenital amaurosis, Stargardt disease, and others. The Gene Wave technology is used for optimal titration and can also be re-dosed by using closed-ended DNA for gene therapy development. The ceDNA is packaged in a lipid nanoparticle that dissolves into the cytoplasm of a cell and heads to the nucleus to produce proteins.

Website: generationbio.com
Social
Email ID: *****@generationbio.com, *****@generationbio.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Acquired

Total Funding

$236M in 3 rounds

Latest Funding Round

Series C, Jan 10, 2020, $*****

Last Known Valuation

$***** as on Dec 15, 2025

Investors

Fidelity Investments & 10 more

Ranked

30^th among 817 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

59 as on Jan 31, 2026

Similar Companies

BridgeBio & 999 more

Exit Details

Acquired by XOMA Corporation (Dec 15, 2025)

View Generation Bio's full profile

Generation Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Generation Bio Co. CIN: 1733294 , United States, Active	Oct 20, 2016	$10M - $50M (As on Dec 31, 2024)	-	-
GENERATION BIO CIN: 814301284 , United States, Active	Dec 31, 2015	-	116 (As on Dec 31, 2024)	-

Generation Bio got acquired by XOMA Corporation on Dec 15, 2025.

Click here to take a look at Generation Bio's acquisition in detail

Generation Bio has raised a total funding of $236M over 3 rounds. Its first funding round was on Jan 04, 2018. Its latest funding round was a Series C round on Jan 10, 2020 for $*****. 10 investors participated in its latest round. Generation Bio has 11 institutional investors.

Here is the list of recent funding rounds of Generation Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2020	5779097	Series C	9519536	2832900	6639250	3290885
Feb 27, 2018	6862771	Series B	5120253	9705120	5282985	Invus & 4 more
Jan 04, 2018	8201518	Series A	3024495	7599113	6844376	Atlas Venture

Access funding benchmarks and valuations. Sign up today!

View details of Generation Bio's funding rounds and investors

The founders of Generation Bio are Mark Angelino, Robert M Kotin and Mark Angelino. Geoff McDonough is the CEO of Generation Bio.

Here are the details of Generation Bio's key team members:

Mark Angelino: Co-Founder & COO of Generation Bio. They serve on the board of 1 company.
Robert M Kotin: Former Co-Founder of Generation Bio and founder of 1 other company.
Mark Angelino: Chief Operating Officer and founder of Generation Bio.
Geoff McDonough: CEO of Generation Bio.

View details of Generation Bio's Founder profiles and Board Members

Generation Bio's employee count trend

Generation Bio has 59 employees as of Jan 26. Here is Generation Bio's employee count trend over the years:

Uncover Generation Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Generation Bio include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Generation Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
9th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
30th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Atlas Venture & 9 others	65/100